cover of episode What Would You Pay to Stay Alive?

What Would You Pay to Stay Alive?

2025/5/27
logo of podcast What Next | Daily News and Analysis

What Next | Daily News and Analysis

AI Deep Dive AI Chapters Transcript
People
D
David Armstrong
Topics
David Armstrong: 作为一名多发性骨髓瘤患者,我亲身体验了Revlimid这种救命药的高昂价格。一颗药的制造成本仅为25美分,但售价却高达近1000美元,这让我难以理解。确诊后,我了解到这种药是沙利度胺的类似物,而沙利度胺曾因导致严重的出生缺陷而臭名昭著。尽管如此,Revlimid仍然是治疗我的疾病的关键。我发现,Celgene公司通过控制分销渠道,阻止通用名药物进入市场,从而长期保持了对Revlimid的垄断。即使现在有了通用名药物,价格也只略有下降,因为Celgene与通用名药物制造商达成了限制竞争的协议。这种高昂的药价不仅影响了我个人,也对整个医疗保健系统造成了负担,许多患者因为无力承担而不得不停止服药或寻求其他途径。我希望能够将更多的资金投入到新药的研发中,让更多的患者受益。

Deep Dive

Shownotes Transcript

A Revlimid pill costs about 25 cents to make, and about a thousand dollars to buy—but it’s keeping him alive, so what choice does he have?

Guest: David Armstrong, investigates healthcare at ProPublica), author of “The Price of Remission).”

Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at__ slate.com/whatnextplus__)__ __to get access wherever you listen.

Podcast production by Ethan Oberman, Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, Isabel Angell, and Rob Gunther.

Learn more about your ad choices. Visit megaphone.fm/adchoices)